Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMUS-CABG
NCT07195149Phase 3Recruiting
- Sponsor
- Medinet Heart Centre
- Start
- Nov 2025
- Primary completion
- Apr 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of prasugrel in Chronic Coronary Syndrome (CCS) (3 arms), sponsored by Medinet Heart Centre. Primary endpoint: Incidence of graft failure at 12 months. Started Nov 2025; status: recruiting.
02
Drugs
prasugrel
03
Conditions
Chronic Coronary Syndrome (CCS)
Beyond the preview
Go deeper on NCT07195149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07195149.